BCI invests in Tolerance Bio’s new treatment aiming to retrain the immune system (opens in new tab)

Beyond Celiac Investments (BCI), the venture philanthropy program of Beyond Celiac, announced an investment in Tolerance Bio Inc. to support advancement of its celiac disease program through early development and preclinical proof of concept. The funding will support Tolerance Bio’s approach to restoring immune tolerance by targeting the thymus, aiming to retrain the immune system […] The post appeared first on <a href="